New Hemophilia A Treatment Approved

Today the US Food & Drug Administration (FDA) has approved a new treatment for children and adults with Hemophilia A (Factor VIII deficiency).  That new treatment is Octapharma’s “Nuwiq”.  It is a B-domain deleted recombinant Factor VIII derived from a human cell-line which has been not chemically modified or fused with another protein.

“Octapharma has been committed to the bleeding disorders community for many years and its decade-long drive to find solutions for Hemophilia A challenges has never wavered,” said Octapharma President Flemming Nielsen via press release. “Early development strategies were integral in the development of Nuwiq and these initial goals have been realized with the FDA approval. Nuwiq has demonstrated safety and efficacy in global clinical trials and has the potential to positively impact patients’ quality of life in the years ahead. Octapharma is dedicated to providing life enhancing and saving therapies for Hemophilia A and looks forward to bringing Nuwiq to the U.S. marketplace.”

Octapharma is one of the largest plasma product manufacturers in the world, offering products like Wilate (von Willebrand Factor) and Octagam (Intravenous Immune Globulin or IVIG).

For more information on Nuwiq, click here.